

## Newborn Screening for Cystic Fibrosis:

### Developing a Program for California

*Friday, August 10, 2001  
9:30 am—5:00 pm*

*DoubleTree Hotel  
2050 Gateway Place  
San Jose, CA 95110*

## Cystic Fibrosis



*Sponsored By:*

California Department of Health Services  
Genetic Disease Branch  
Public Health Institute  
Cystic Fibrosis Research Inc.

## Conference Purpose

The California Department of Health Services Genetic Disease Branch (GDB) is preparing to expand the current Newborn Screening Program to include cystic fibrosis (CF), a common lethal genetic disease. The purpose of the conference is to combine expertise from current CF screening programs, CF care providers, researchers, and other key stakeholders:

- To provide information about newborn screening for CF
- To discuss issues concerning the addition of CF to the current Newborn Screening Program
- To present preliminary findings on mutation frequencies in California Hispanics.

## Conference Audience

Clinicians, affected families, laboratory scientists, genetic counselors, state and regional Newborn Screening Program staff, and researchers in CF.

### CONTINUING EDUCATION

This is an activity offered by the Genetic Disease Branch of the **California Department of Health Services**, a CMA-accredited provider. Physicians attending this course may report up to 6 hours of Category 1 credits toward the California Medical Association's Certification in Continuing Medical Education and the American Medical Association's Physician's Recognition Award.

The **Genetic Disease Branch** is approved by the California Board of Registered Nursing, Provider Number CEP 12857, for 6 contact hours.

The NLTN Pacific Office is approved by the **California Department of Health Services** as a CA CLS Accrediting Agency (#0022). This program qualifies for 6 contact hours of continuing education for California clinical laboratory licensees.

### Conference Registration Form

\$25.00 per person  
(one form per registrant)

Name

Employer

Address

City

State

Zip Code

Email Address

Phone

Fax

**Please register by July 31, 2001**, as seating space is limited. Registrations received after that date or on-site will be assessed a \$30.00 late fee.

**Cancellation Policy:** Full refunds will be granted for all cancellations received in writing by July 31, 2001. No refunds will be provided after this date.

**Please make check payable to:**  
Public Health Institute

### Mail to:

Genetic Disease Branch  
2151 Berkeley Way, Annex 4  
Berkeley, CA 94704-10011  
Attention: CF Screening Conference

For more information contact:  
Suzanne Young  
510-883-6023

# Newborn Screening for Cystic Fibrosis:

## Developing a Program for California

### Meeting Information

#### Location

DoubleTree Hotel  
2050 Gateway Place  
San Jose, CA 95110  
Phone: (408) 453-4000

*\*DoubleTree provides free parking and  
complimentary airport shuttle*

#### Date/Time

Friday, August 10, 2001  
9:30am-5:00pm  
Registration from 8:30-9:30am

#### Registration Fee

\$25.00/per person  
(includes lunch and breaks)

#### For more information

Contact Suzanne Young  
510-883-6023

### Speakers

Frank Accurso, M.D., *CF Center Director,  
University of Colorado, The Children's  
Hospital*

Lucy Crain, M.D., *Past Chair, California  
District, American Academy of Pediatrics*

Gerd Cropp, M.D., *CF Center Director,  
University of California, San Francisco*

George Cunningham, M.D., *Chief,  
Genetic Disease Branch*

John Eastman, Ph.D., *Clinical Research  
Chemist, Genetic Disease Lab*

Scott Grosse, Ph.D., *Health Economist,  
Centers for Disease Control and Preven-  
tion*

Elizabeth Kearney, M.S., *Genetic Coun-  
selor, Kaiser Permanente Medical Care*

Martin Kharrazi, Ph.D., *Research Scientist,  
Genetic Disease Branch*

Michael Rock, M.D., Ph.D., *CF Center Di-  
rector, University of Wisconsin Medical  
School*

Tom Stout, *Parent*

### Learning Objectives

At the conclusion of this conference, the participant will be able to:

- Describe the benefits of early detection of CF through newborn screening.
- Summarize the historical forces influencing the development of CF newborn screening.
- Explain the laboratory methods of newborn screening for CF.
- Identify ways current programs and systems (newborn screening, CF care centers and clinics, State approved laboratories, etc.) will be affected by implementation of a CF newborn screening program.
- Explain how the CF mutation study at the GDB will help create a screening test that is effective in California's heterogeneous population.

### Conference Supporters

Pacific Southwest Regional  
Genetics Network

Applied Biosystems

PerkinElmer Life Sciences

Genentech

Roche Molecular Biochemicals